US · Healthcare · Biotechnology
EPS came in at 1.94 against a street estimate of 0.85 — a beat of 128.2%.
Analysts rate BioNTech SE a buy (14 buy, 7 hold, 0 sell out of 21) with an average price target of $117.29.
MIXED BioNTech posted weak Q2 revenue (EUR 106M, down 59% YoY) due to collapsed COVID demand and inventory use. Late-stage pipeline advanced with pumitamig Phase II data across tumors; gotistobart showed strong OS signals. FY26 guidance cut 21% midpoint to EUR 1.6–1.9B. Q2 2026 COVID vaccine demand weakness spans all geographies; Germany most acute due to direct market model and inventory drawdown strategy. Analysts pressed on Elfe-D competitive positioning (safety profile vs peers), revenue miss drivers (COVID 80%, lost milestone 20%), and ROSETTA LUNG-02 timing (event-driven; PFS interim before OS). Management emphasized data-driven approach, partner efficiency, and cautious optimism on late-stage readouts despite guidance reset. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 3.01% |
| PRIMECAP Management Company | 1.50% |
| Dodge & Cox | 1.46% |
| Flossbach von Storch AG | 0.89% |
| T. Rowe Price Investment Management,Inc. | 0.82% |
| BlackRock Inc | 0.74% |
| Temasek Holdings Ltd. | 0.60% |
| BNP Paribas Arbitrage, SA | 0.53% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue was €1,289.2 million, down from €1,518.9 million in Q3 2025. • Q3 2026 operating profit was €125.0 million, compa | 2026-11-03 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was €1,289.2 million, down from €1,518.9 million in third-quarter 2025, mainly because of lower COVID-1 | 2026-11-03 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • BioNTech and Bristol Myers Squibb reported first global Phase 2 ROSETTA Lung-107 data for investigational pumitamig plus docetaxel | 2026-10-26 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • BioNTech and DualityBio reported topline results from the global Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan (BNT323/ | 2026-10-26 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • BioNTech announced a clinical trial collaboration and supply agreement with Gilead Sciences to test pumitamig with Gilead’s TROP2- | 2026-10-22 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • BioNTech will present 16 abstracts covering 10 tumor types at the ESMO 2026 Congress in Madrid, October 23–27, 2026. • The compan | 2026-10-19 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • BioNTech’s AHEAD-MERIT Phase 2/3 trial did not meet its first dual primary endpoint: progression-free survival (PFS). • BNT113 pl | 2026-10-13 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • BioNTech announced the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft (“KPMG”) as its new independent auditor for the | 2026-09-18 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioNTech SE — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.